Pelthos to Merge With Castle Creek in Skin-Therapy Expansion
+2 new sources since this summary was written
Pelthos Therapeutics agreed on October 30, 2026 to merge with Castle Creek Biosciences, combining Pelthos’ marketed dermatology products with Castle Creek’s cell and gene therapy pipeline. Castle Creek stockholders will receive 5.2 million Pelthos shares at closing and may qualify for as much as $300 million in milestone payments tied to D-Fi, an investigational Phase 3 therapy for dystrophic epidermolysis bullosa. Pelthos expects completion during the first quarter of 2027, subject to required conditions including Castle Creek stockholder approval.
Why it matters
The transaction gives Pelthos exposure to Castle Creek’s late-stage D-Fi program and adds cell and gene therapy capabilities to its dermatology business. The share issuance will dilute existing Pelthos holders, while any milestone payments would be contingent on D-Fi development and commercial achievements.
Key facts
- 1Pelthos will issue 5.2 million common shares to Castle Creek stockholders at the merger closing. rttnews.com
- 2Castle Creek stockholders may receive up to $300 million in milestone payments linked to D-Fi. stocktitan.net
- 3The merger is targeted for completion by the end of the first quarter of 2027, subject to closing conditions and Castle Creek stockholder approval. rttnews.com
- 4D-Fi is being developed in a Phase 3 program for dystrophic epidermolysis bullosa. rttnews.com
Open questions
- Closing still depends on customary conditions, including approval by Castle Creek stockholders.
- The materials report different intraday PTHS price declines and prices, reflecting different reporting times.
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.